Tag: data collection

In this 2025 product transparency update, BloodVitals details how its pulse oximeter supports real-time blood vitals tracking through non-invasive technology designed for seniors and at-home wellness users. The release explores the shift toward pain-free health monitoring, the rising demand for accessible oxygen level tools, and the increasing role of pulse oximeters in managing vital signs outside clinical settings.

In this 2025 product transparency update, BloodVitals details how its pulse oximeter supports real-time blood vitals tracking through non-invasive technology designed for seniors and at-home wellness users. The release explores the shift toward pain-free health monitoring, the rising demand for accessible oxygen level tools, and the increasing role of pulse oximeters in managing vital signs outside clinical settings.

TEMPE, Ariz., July 8, 2025 /PRNewswire/ -- Economic activity in the hospital subsector contracted in June after 21 consecutive months of growth, say the nation's...

HOUSTON, July 7, 2025 /PRNewswire/ -- Nauticus Robotics, Inc. (NASDAQ: KITT), a leading innovator in autonomous subsea robotics and software solutions, today announced completion of...

NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global digital twin market is observing significant...

NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global digital twin market is observing significant...

Business Activity Index at 54.2%; New Orders Index at 51.3%; Employment Index at 47.2%; Supplier Deliveries Index at 50.3% TEMPE, Ariz., July 3, 2025 /PRNewswire/...

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.